Skip to main content
. 2023 Nov 6;24(21):16011. doi: 10.3390/ijms242116011

Figure 2.

Figure 2

Auraptene induces AMPK activation in LNCaP cells. (a–c) LNCaP cells were treated with auraptene at the indicated concentrations for 8 h. AICAR (1 mM) was employed as a positive control. (a) AMPKα, phospho-AMPKα, ACC, phospho-ACC, and actin in LNCaP cells were detected using immunoblotting. (b,c) Quantification of relative band intensities (pAMPK/AMPK (b) and pACC/ACC (c)) (n = 4). (d) Western blot analysis. LNCaP cells were treated with 30 μM auraptene for 1, 2, 4, 8, or 24 h. (e) LNCaP cells were treated with 30 μM auraptene for 1 h, and the intracellular ADP/ATP ratio was determined using an ADP/ATP Ratio Assay Kit (n = 4). (f) Western blot analysis. LNCaP cells were treated with 30 μM auraptene for 1 h. (* p < 0.05, *** p < 0.001).